Forward osmosis–membrane distillation hybrid system for desalination using mixed trivalent draw solution

© 2020 Elsevier B.V. Finding suitable draw solutions is still a major problem when developing FO technologies. This study represents the first time a mixed trivalent draw solution containing of EDTA–2Na and Na3PO4 was systemically studied for FO performance. The objective here was to achieve simultaneously low reverse salt flux and high water flux. The FO results showed that the mixed trivalent draw solution-based 0.3 M EDTA–2Na and 0.55 M Na3PO4 underwent higher water flux (Jw = 9.17 L/m2⋅h) than that of pure 0.85 M EDTA-2Na (Jw = 7.02 L/m2⋅h) due to its lower viscosity. Additionally, the specific reverse salt flux caused by mixing 0.3 M EDTA–2Na with 0.55 M Na3PO4 draw solution was only 0.053 g/L using DI water as the feed solution. Donnan equilibrium force and formed complexation of [EDTANa]3-, [HPO4Na]- with the FO membrane are believed to constitute the main mechanism for minimizing salt leakage from the mixed draw solution. Moreover, the FO desalination process utilizing the mixed trivalent draw solution achieved water fluxes of 6.12 L/m2⋅h with brackish water (TDS = 5000 mg/L) and 3.10 L/m2⋅h with seawater (TDS = 35,000 mg/L) as the feed solution. Lastly, diluted mixed trivalent draw solution following the FO process was effectively separated using the MD process with salt rejection >99.99% at a mild feed temperature of 55 °C

Geometric maximal operators and BMO on product bases

We consider the problem of the boundedness of maximal operators on BMO on shapes in $\mathbb{R}^n$. We prove that for bases of shapes with an engulfing property, the corresponding maximal function is bounded from BMO to BLO, generalising a known result of Bennett for the basis of cubes. When the basis of shapes does not possess an engulfing property but exhibits a product structure with respect to lower-dimensional shapes coming from bases that do possess an engulfing property, we show that the corresponding maximal function is bounded from BMO to a space we define and call rectangular BLO

Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area

<p>Abstract</p> <p>Background</p> <p>Drug resistance of falciparum malaria is a global problem. Sulphadoxine/pyrimethamine-resistant and mefloquine-resistant strains of falciparum malaria have spread in Southeast Asia at lightning speed in 1980s-1990s, and the Cambodia-Thailand border is one of the malaria epidemic areas with the most severe forms of multi-drug resistant falciparum malaria.</p> <p>Methods</p> <p>Artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine phosphate (DHP) and artemether-lumefantrine (AL) were used to treat 110, 55 and 55 uncomplicated malaria patients, respectively. The total dosage for adults is 1,750 mg (four tablets, twice over 24 hours) of AP, 2,880 mg (eight tablets, four times over two days) of DHP, and 3,360 mg (24 tablets, six times over three days) of AL. The 28-day cure rate, parasite clearance time, fever clearance time, and drug tolerance of patients to the three drugs were compared. All of the above methods were consistent with the current national guidelines.</p> <p>Results</p> <p>The mean parasite clearance time was similar in all three groups (66.7 ± 21.9 hrs, 65.6 ± 27.3 hrs, 65.3 ± 22.5 hrs in AP, DHP and AL groups, respectively), and there was no remarkable difference between them; the fever clearance time was also similar (31.6 ± 17.7 hrs, 34.6 ± 21.8 hrs and 36.9 ± 15.4 hrs, respectively). After following up for 28-days, the cure rate was 95.1%(97/102), 98.2%(54/55) and 82.4%(42/51); and the recrudescence cases was 4.9%(5/102), 1.8%(1/55) and 17.6%(9/51), respectively. Therefore, the statistical data showed that 28-day cure rate in AP and DHP groups was superior to AL group obviously.</p> <p>The patients had good tolerance to all the three drugs, and some side effects (anoxia, nausea, vomiting, headache and dizziness) could be found in every group and they were self-limited; patients in control groups also had good tolerance to DHP and AL, there was no remarkable difference in the three groups.</p> <p>Conclusions</p> <p>AP, DHP and AL all remained efficacious treatments for the treatment of falciparum malaria in Cambodia-Thailand border area. However, in this particular setting, the AP regimen turned out to be favourable in terms of efficacy and effectiveness, simplicity of administration, cost and compliance.</p> <p>Trial Registration</p> <p>The trial was registered at <it>Chinese Clinical Trial Register </it>under identifier 2005L01041.</p